Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

genzyme europe b.v - inmunoglobulina de conejo antitimocitos humanos - inmunoglobulina de conejo antitimocitos humanos....25 mg.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabbit antithymocyte immunoglobulin, quantity: 25 mg - injection, powder for - excipient ingredients: sodium chloride; glycine; mannitol - thymoglobuline (rabbit anti-human thymocyte immunoglobulin) is indicated for the prophylaxis of graft rejection in renal transplantation; treatment of steroid-resistant or moderate to severe renal transplant rejection: and treatment of refractory or relapsing aplastic anaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - antithymocyte immunoglobulin 25mg (rabbit) - powder for infusion - 25 mg - active: antithymocyte immunoglobulin 25mg (rabbit) excipient: glycine mannitol sodium chloride - thymoglobuline® (rabbit anti - human thymocyte immunoglobulin) is indicated for the prophylaxis of graft rejection in renal transplantation; treatment of steroid - resistant or moderate to severe renal transplant rejection and in the prophylaxis of graft rejection in heart transplantation.

United States - English - NLM (National Library of Medicine)

genzyme corporation - lapine t-lymphocyte immune globulin (unii: d7rd81he4w) (lapine t-lymphocyte immune globulin - unii:d7rd81he4w) - lapine t-lymphocyte immune globulin 5 mg in 1 ml - thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. thymoglobulin is to be used in conjunction with concomitant immunosuppression. thymoglobulin is contraindicated in patients with history of allergy or anaphylactic reaction to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression [see warnings and precautions (5.2, 5.5) and adverse reactions (6.2)] . risk summary animal reproduction studies have not been conducted with thymoglobulin. it is also not known whether thymoglobulin can cause fetal harm. thymoglobulin should be given to a pregnant woman only if the benefit outweighs the risk. risk summary thymoglobulin has not been studied in nursing women. it is not known whether this drug is excreted in human milk. because other immunoglobulins are excreted in human milk, breastfeeding should be discontinued during thymoglobulin therapy. contracepti

Israel - English - Ministry of Health

sanofi israel ltd - immunoglobulin rabbit anti-human thymocyte - powder for concentrate for solution for infusion - immunoglobulin rabbit anti-human thymocyte 25 mg/vial - antithymocyte immunoglobulin (rabbit) - antithymocyte immunoglobulin (rabbit) - immunosuppression in transplantation: prevention and treatment of graft rejection. treatment of acute graft versus host disease (gvhd). hematology treatment of aplastic anemia.

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - rabbit anti-human thymocyte immunoglobulin - powder for solution for infusion - 25 milligram(s) - selective immunosuppressants; antithymocyte immunoglobulin (rabbit)

Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - rabbit immunoglobulin - powder for solution for infusion - rabbit immunoglobulin 25 mg - immunosuppressants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - antithymocyte immunoglobulin (rabbit) - powder and solvent for solution for infusion - 25mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each vial contains rabbit anti-human thymocyte immunoglobulin 25,0 mg